

CLAIM LISTING

1-28. Canceled.

29. (Currently amended) A method of treating chronic lymphocytic leukemia in a human patient, comprising administering an ~~unlabeled~~ anti-CD20 antibody to the patient in an amount effective to treat the chronic lymphocytic leukemia, wherein the method does not include treatment with a radiolabeled antibody.

30. (Previously presented) A method according to claim 29, wherein the anti-CD20 antibody is administered to the patient at a dosage of about 0.001 to about 30 mg/kg.

31. (Previously presented) A method according to claim 29, wherein the anti-CD20 antibody is administered to the patient at a dosage of about 0.01 to about 25 mg/kg.

32. (Previously presented) A method according to claim 29, wherein the anti-CD20 antibody is administered to the patient at a dosage of about 0.1 to about 20 mg/kg.

33. (Previously presented) A method according to claim 29, wherein the anti-CD20 antibody is administered to the patient at a dosage of about 375 mg/m².

34. (Currently amended) A method of treating chronic lymphocytic leukemia in a human patient, comprising administering an ~~unlabeled~~ anti-CD20 antibody to the patient in an amount effective to treat the chronic lymphocytic leukemia, wherein the anti-CD20 antibody is administered to the patient at a dosage of about 500 to about 1500 mg/m².

35. (Previously presented) A method according to claim 34, wherein the anti-CD20 antibody is administered to the patient at a dosage of about 500 mg/m².

36. (Previously presented) A method according to claim 34, wherein the anti-CD20 antibody is administered to the patient at a dosage of about 650 mg/m².
37. (Previously presented) A method according to claim 34, wherein the anti-CD20 antibody is administered to the patient at a dosage of about 825 mg/m².
38. (Previously presented) A method according to claim 34, wherein the anti-CD20 antibody is administered to the patient at a dosage of about 1500 mg/m².
39. (Previously presented) A method according to claim 29 or 34, wherein the patient has relapsed following previous treatment for the chronic lymphocytic leukemia.
40. (Previously presented) A method according to claim 29 or 34, wherein the patient is refractory to a treatment previously administered for the chronic lymphocytic leukemia.
41. (Currently amended) A method according to claim 40, wherein the patient is refractory to ~~fludaribine~~ fludarabine.
42. (Previously presented) A method according to claim 29 or 34, wherein the anti-CD20 antibody is a chimeric antibody.
43. (Previously presented) A method according to claim 42, wherein the anti-CD20 antibody is rituximab.
44. (Previously presented) A method according to claim 29 or 34, wherein the anti-CD20 antibody is a humanized antibody.
45. (Previously presented) A method according to claim 29 or 34, wherein the anti-CD20 antibody is a human antibody.

46. (Previously presented) A method according to claim 29 or 34, wherein the anti-CD20 antibody comprises a CD20-binding fragment of a chimeric, humanized, or human antibody.
47. (Previously presented) A method according to claim 29 or 34, wherein the anti-CD20 antibody is administered to the patient repeatedly.
48. (Previously presented) A method according to claim 47, wherein the repeated administration comprises a stepped-up dosing schedule.
49. (Previously presented) A method according to claim 47, wherein the anti-CD20 antibody is administered to the patient weekly.
50. (Previously presented) A method according to claim 47, wherein the anti-CD20 antibody is administered to the patient weekly for about 2 to 10 weeks.
51. (Previously presented) A method according to claim 47, wherein the anti-CD20 antibody is administered to the patient biweekly.
52. (Previously presented) A method according to claim 47, wherein the anti-CD20 antibody is administered to the patient monthly.
53. (Previously presented) A method according to claim 29 or 34, wherein the anti-CD20 antibody is administered to the patient parenterally.
54. (Previously presented) A method according to claim 53, wherein the anti-CD20 antibody is administered to the patient by intravenous infusion.

55. (Currently amended) A method of treating chronic lymphocytic leukemia in a human patient, comprising administering an ~~unlabeled~~ anti-CD20 antibody to the patient in an amount effective to treat the chronic lymphocytic leukemia, wherein the anti-CD20 antibody therapy is combined with chemotherapy, wherein the method does not include treatment with a radiolabeled antibody.
56. (Previously presented) A method according to claim 55, wherein the anti-CD20 antibody is administered to the patient at a dosage of about 0.001 to about 30 mg/kg.
57. (Previously presented) A method according to claim 55, wherein the anti-CD20 antibody is administered to the patient at a dosage of about 0.01 to about 25 mg/kg.
58. (Previously presented) A method according to claim 55, wherein the anti-CD20 antibody is administered to the patient at a dosage of about 0.1 to about 20 mg/kg.
59. (Previously presented) A method according to claim 55, wherein the anti-CD20 antibody is administered to the patient at a dosage of about 375 mg/m².
60. (Currently amended) A method of treating chronic lymphocytic leukemia in a human patient, comprising administering an ~~unlabeled~~ anti-CD20 antibody to the patient in an amount effective to treat the chronic lymphocytic leukemia, wherein the anti-CD20 antibody is administered to the patient at a dosage of about 500 to about 1500 mg/m², and wherein the anti-CD20 antibody therapy is combined with chemotherapy.
61. (Previously presented) A method according to claim 60, wherein the anti-CD20 antibody is administered to the patient at a dosage of about 500 mg/m².
62. (Previously presented) A method according to claim 60, wherein the anti-CD20 antibody is administered to the patient at a dosage of about 650 mg/m².

63. (Previously presented) A method according to claim 60, wherein the anti-CD20 antibody is administered to the patient at a dosage of about 825 mg/m².
64. (Previously presented) A method according to claim 60, wherein the anti-CD20 antibody is administered to the patient at a dosage of about 1500 mg/m².
65. (Previously presented) A method according to claim 55 or 60, wherein the patient has relapsed following previous treatment for the chronic lymphocytic leukemia.
66. (Previously presented) A method according to claim 55 or 60, wherein the patient is refractory to a treatment previously administered for the chronic lymphocytic leukemia.
67. (Currently amended) A method according to claim 66, wherein the patient is refractory to ~~fludaribine~~ fludarabine.
68. (Previously presented) A method according to claim 55 or 60, wherein the anti-CD20 antibody is a chimeric antibody.
69. (Previously presented) A method according to claim 68, wherein the anti-CD20 antibody is rituximab.
70. (Previously presented) A method according to claim 55 or 60, wherein the anti-CD20 antibody is a humanized antibody.
71. (Previously presented) A method according to claim 55 or 60, wherein the anti-CD20 antibody is a human antibody.
72. (Previously presented) A method according to claim 55 or 60, wherein the anti-CD20 antibody comprises a CD20-binding fragment of a chimeric, humanized, or human antibody.

73. (Previously presented) A method according to claim 55 or 60, wherein the anti-CD20 antibody is administered to the patient repeatedly.
74. (Previously presented) A method according to claim 73, wherein the repeated administration comprises a stepped-up dosing schedule.
75. (Previously presented) A method according to claim 73, wherein the anti-CD20 antibody is administered to the patient weekly.
76. (Previously presented) A method according to claim 73, wherein the anti-CD20 antibody is administered to the patient weekly for about 2 to 10 weeks.
77. (Previously presented) A method according to claim 73, wherein the anti-CD20 antibody is administered to the patient biweekly.
78. (Previously presented) A method according to claim 73, wherein the anti-CD20 antibody is administered to the patient monthly.
79. (Previously presented) A method according to claim 55 or 60, wherein the anti-CD20 antibody is administered to the patient parenterally.
80. (Previously presented) A method according to claim 79, wherein the anti-CD20 antibody is administered to the patient by intravenous infusion.
81. (Previously presented) A method according to claim 55 or 60, wherein the anti-CD20 antibody therapy and the chemotherapy are administered to the patient concurrently.
82. (Previously presented) A method according to claim 55 or 60, wherein the chemotherapy comprises chlorambucil.

83. (Previously presented) A method according to claim 55 or 60, wherein the chemotherapy comprises cyclophosphamide.
84. (Currently amended) A method according to claim 83, wherein the chemotherapy comprises cyclophosphamide, ~~Oneovin~~ vincristine, and prednisone (COP).
85. (Currently amended) A method according to claim 83, wherein the chemotherapy comprises cyclophosphamide, ~~Oneovin~~ vincristine, prednisone, and doxorubicin (CHOP).
86. (Previously presented) A method according to claim 55 or 60, wherein the chemotherapy comprises vincristine.
87. (Previously presented) A method according to claim 55 or 60, wherein the chemotherapy comprises prednisone.
88. (Previously presented) A method according to claim 55 or 60, wherein the chemotherapy comprises doxorubicin.
89. (Previously presented) A method according to claim 55 or 60, wherein the chemotherapy comprises fludarabine.
90. (Previously presented) A method according to claim 55 or 60, wherein the chemotherapy comprises methotrexate.
91. (Previously presented) A method according to claim 55 or 60, wherein the chemotherapy comprises cisplatin.
92. (Currently amended) A method according to claim 55 or 60, wherein the chemotherapy comprises ~~toremifene~~ toremifene.

93. (Previously presented) A method according to claim 55 or 60, wherein the chemotherapy comprises tamoxifen.
94. (Currently amended) A method of treating chronic lymphocytic leukemia in a human patient, comprising administering an ~~unlabeled~~ anti-CD20 antibody to the patient in an amount effective to treat the chronic lymphocytic leukemia, wherein the patient is refractory to ~~fludarabine~~ fludarabine previously administered for the chronic lymphocytic leukemia.
95. (New) A method according to claim 34, 60, or 94, wherein the method does not include treatment with a radiolabeled antibody.
96. (New) A method according to claim 34, 60, or 94, wherein radiation is not used in conjunction with the anti-CD20 antibody.
97. (New) A method of treating chronic lymphocytic leukemia in a human patient, comprising administering a therapeutic anti-CD20 antibody to the patient in an amount effective to treat the chronic lymphocytic leukemia, wherein radiation is not used in conjunction with the therapeutic anti-CD20 antibody.
98. (New) A method of treating chronic lymphocytic leukemia in a human patient, comprising administering a therapeutic anti-CD20 antibody to the patient in an amount effective to treat the chronic lymphocytic leukemia, wherein the anti-CD20 antibody therapy is combined with chemotherapy, and wherein radiation is not used in conjunction with the therapeutic anti-CD20 antibody.